Hikma Pharmaceuticals Plc Dividend Declaration (9221N)

TIDMHIK

RNS Number : 9221N

Hikma Pharmaceuticals Plc

04 October 2012

Hikma Pharmaceuticals PLC

Interim Dividend for 2012

LONDON, 4 October 2012 - Hikma Pharmaceuticals PLC ("the Company") advises that, as previously announced with the interim results, the interim dividend of 6.0 cents per will be paid on 08 October 2012 to shareholders on the register on 31 August 2012.

Shareholders who have elected to receive their dividend in Pounds Sterling will receive 3.694 pence per Ordinary Share (exchange rate US$1.6241 to GBPGBP1).

Shareholders who have elected to receive their dividend in Jordanian Dinar will receive 4.248 qirsh (piastres) per Ordinary Share (exchange rate US$0.708 to JOD1).

- ENDS -

Enquiries:

 
 Hikma Pharmaceuticals PLC 
 Peter Speirs 
  Company Secretary              +44 20 7399 2670 
 Susan Ringdal 
  Investor Relations Director    +44 20 7399 2670

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non--branded generic and in--licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DIVMIBPTMBTMMRT

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024